4//SEC Filing
DiRocco Derek 4
Accession 0000950170-24-064848
CIK 0001785530other
Filed
May 23, 8:00 PM ET
Accepted
May 24, 7:52 PM ET
Size
6.0 KB
Accession
0000950170-24-064848
Insider Transaction Report
Form 4
DiRocco Derek
Director
Transactions
- Award
Stock Option (right to buy)
2024-05-24+17,500→ 17,500 totalExercise: $4.88Exp: 2034-05-23→ Common Stock (17,500 underlying)
Footnotes (2)
- [F1]The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
Documents
Issuer
Werewolf Therapeutics, Inc.
CIK 0001785530
Entity typeother
Related Parties
1- filerCIK 0001792061
Filing Metadata
- Form type
- 4
- Filed
- May 23, 8:00 PM ET
- Accepted
- May 24, 7:52 PM ET
- Size
- 6.0 KB